CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 580 enrolled
Drug / intervention
Ticagrelor 90 MG +1 moredrug
Likely dose
Ticagrelor 90 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06120725
NCT06120725Phase 3Completed
CompareCT.gov

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial

Kafrelsheikh University·interventional·Posted Nov 7, 2023·Updated Dec 29, 2023

In Brief

A Phase 3 clinical trial evaluating Ticagrelor 90 MG and Clopidogrel for Ischemic Stroke. Completed, enrolled 580 participants across 1 site.

Detailed Summary

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedNov 7, 2023
Enrollment StartSep 1, 2021
Primary CompletionSep 1, 2023
Study CompletionNov 1, 2023
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 2.6 years ago

Interventions

Ticagrelor 90 MGdrug

Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

Clopidogreldrug

Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.